

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1.-10. (Canceled)

11. (Currently amended) ~~A pharmaceutical composition for~~ A method for treatment of abnormal growth of a smooth muscle cell, said method comprising administering an effective amount of a polypeptide to a subject in need of such treatment, wherein said polypeptide comprises according to claim 1 or 2, in association with a pharmaceutically acceptable diluent and/or carrier;

(i) an amino acid sequence as shown in SEQ ID NO. 13 or 14, or

(ii) an amino acid sequence which is at least 90% homologous to the amino acid sequence shown in SEQ ID NO. 13 or 14, or

(iii) a fragment of (i) or (ii) where said fragment inhibits proliferation of smooth muscle cells.

12. (Currently amended) ~~A pharmaceutical composition for~~ A method of treatment of arteriosclerosis, restenosis after PTCA, or myosarcoma, said method comprising administering a an effective amount of a polypeptide to a subject in need of such treatment, wherein said polypeptide comprises according to claim 1 or 2, in association with a pharmaceutically acceptable diluent and/or carrier;

(i) an amino acid sequence as shown in SEQ ID NO. 13 or 14, or  
(ii) an amino acid sequence which is at least 90% homologous to the amino acid  
sequence shown in SEQ ID NO. 13 or 14, or

(iii) a fragment of (i) or (ii) where said fragment inhibits proliferation of smooth muscle  
cells.

13. (Currently amended) ~~An in vitro screening method for an antagonist or agonist of~~  
~~the polypeptide according to claim 1 or 2, comprising;~~

a) contacting a cell with a test compound and ~~said~~ a polypeptide, said polypeptide  
comprising;

(i) an amino acid sequence as shown in SEQ ID NO. 13 or 14, or  
(ii) an amino acid sequence which is at least 90% homologous to the amino acid  
sequence shown in SEQ ID NO. 13 or 14, or

(iii) a fragment of (i) or (ii) where said fragment inhibits proliferation of smooth muscle  
cells and a test compound,

b) determining a result on cell growth of said contact, and

c) comparing said result with a second result from a control experiment, wherein  
said control experiment comprises contacting a cell ~~is contacted with the~~ said polypeptide in the  
absence of the test compound, thereby identifying compounds that modulate the effects of said  
polypeptide on said cell.

14. (Canceled)

15. (Canceled)